Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | POLD1 | P28340 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3205916 | 0.90 | TYMS (0.43) | TYMSPOLBPOLA1POLD1 | |
| SCHEMBL16675570 | 0.86 | TYMS (0.36) | TYMSPOLB | |
| SCHEMBL14979297 | 0.86 | TYMS (0.36) | TYMSPOLB | |
| SCHEMBL16104239 | 0.86 | TYMS (0.36) | TYMSPOLB | |
| SCHEMBL16086287 | 0.86 | TYMS (0.39) | TYMSP2RY2P2RY4P2RY6POLB | |
| SCHEMBL16086184 | 0.85 | TYMS (0.38) | TYMSP2RY2P2RY4P2RY6POLB | |
| SCHEMBL16085894 | 0.80 | TYMS (0.34) | TYMS | |
| SCHEMBL16541272 | 0.78 | TYMS (0.48) | TYMSPOLB | |
| SCHEMBL888169 | 0.78 | TYMS (0.48) | TYMSPOLB | |
| SCHEMBL18643292 | 0.78 | TYMS (0.35) | TYMSP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781599-B1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9873879-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170073683-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2017-03-16 | — | — | US | disclosed |
| US-9540650-B2 | Nucleic acid fragment binding to target protein | TAGCYX BIOTECHNOLOGIES (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TAGCYX BIOTECHNOLOGIES (JP) | 2015-04-30 | — | — | US | disclosed |
| EP-2781599-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | Riken (JP) | 2014-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119254-A1 | NUCLEIC ACID FRAGMENT BINDING TO TARGET PROTEIN | TARBP1, DNTT, FABP1 | TYMS 558/4885P2RY2 3276/4885P2RY4 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.